-+ 0.00%
-+ 0.00%
-+ 0.00%
CG Oncology Celebrates Defining Milestone As Bladder Cancer Trial Succeeds
Share
Listen to the news

CG Oncology Inc. (NASDAQ:CGON) on Monday announced positive topline results from its Phase 3 PIVOT-006 trial, which Arthur Kuan, chairman, president, and CEO of CG Oncology, called a defining milestone for the company.

Kuan stated that the data position cretostimogene grenadenorepvec as the first and only therapeutic candidate to show a significant recurrence benefit in a pivotal Phase 3 study for intermediate-risk and high-grade Ta NMIBC, prompting the company to advance two BLA filings in 2027.

PIVOT-006 Trial Delivers 68% Recurrence Risk Reduction

The registrational PIVOT-006 study evaluated adjuvant intravesical cretostimogene following complete tumor resection in patients with intermediate-risk and high-grade Ta ≤3 cm NMIBC.

Currently, no U.S. FDA-approved adjuvant treatments exist for this population of roughly 50,000 patients.

PIVOT-006 met its primary endpoint, delivering statistically significant and clinically meaningful improvements over the control arm.

Over a median follow-up of 17 months as of Oct. 26, 2026, cretostimogene reduced recurrence risk by 68% compared with the control arm, achieving a hazard ratio of 0.32.

Patients generally tolerated cretostimogene well, with safety results matching previous studies.

The study recorded no Grade 3 or greater treatment-related adverse events and no treatment-related discontinuations.

Expanded BLA Strategy Targets Broader Bladder Cancer Populations

Combined with CG Oncology’s existing data in high-risk BCG-unresponsive NMIBC, the PIVOT-006 results could substantially expand the patient populations eligible for cretostimogene if approved.

Kuan noted that the company is working quickly to finish its BLA filing in intermediate-risk and high-grade Ta NMIBC in the second quarter of 2027.

Following FDA feedback, CG Oncology also plans to expand its initial BLA submission in BCG-unresponsive NMIBC.

Rather than focusing only on patients with CIS with or without papillary tumors, the submission will include patients with high-grade papillary-only disease to achieve a label reflecting the full range of BCG-unresponsive patients.

To incorporate the extra data, CG Oncology now expects to complete that submission before the end of March 2027.

The company has finished all BLA-enabling manufacturing activities supporting both regulatory filings.

CGON Price Action: CG Oncology shares were up 16.25% at $86.49 at the time of publication on Monday. The stock is trading at a new 52-week high, according to Benzinga Pro data.

Image via Shutterstock

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending